Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma

Cancer Letters

Volumn 308, Issue 1, 2011, Pages 54-61

  Lange, Tobias ^a   Nentwich, Michael F ^a   Lüth, Manuel ^a   Yekebas, Emre ^a   Schumacher, Udo ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Angiogenesis; Esophageal adenocarcinoma; HER 2 neu; Spontaneous metastasis xenograft model; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958163104     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.013     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. C.A. Cancer J. Clin. 2006, 56(2006):106-130.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. C.A. Cancer J. Clin. 2002, 55(2005):74-108.
3. Devesa S.S., Blot W.J., Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
4. al-Kasspooles M., Moore J.H., Orringer M.B., Beer D.G. Amplification and overexpression of EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer 1993, 54:213-219.
5. Reichelt U., Duesedau P., Tsourlakis M.Ch., et al. Frequent homogeneous HER-2 amplification and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 2007, 20:120-129.
6. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti- HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
7. Moasser M.M. The oncogene HER2: its signalling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:254-264.
8. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell. Biol. 2009, 21:177-184.
9. Kurokawa H., Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 2003, 9:S511-515.
10. Esteva F.J., Yu D., Hung M.C., Hortobagyi G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:98-107.
11. Mills G.B., Kohn E., Lu Y., et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Sem. Oncol. 2003, 30:93-104.
12. Emens L.A. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am. J. Ther. 2005, 12:243-253.
13. Safran H., DiPetrillo T., Akerman P., et al. Phase I/ II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67:405-409.
14. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (HerceptinTM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998, 58:2825-2831.
15. Jojovic M., Schumacher U. Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett. 2000, 152:151-156.
16. Weidner N., Joseph P.S., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324:1-8.
17. Coene E.D., Schelfhout V., Winkler R.A., et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch. 1997, 430:365-372.
18. Gros S.J., Kurschat N., Dohrmann T., et al. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol. Cancer Ther. 2010, 9:2037-2045.
19. Kalinina T., Bockhorn M., Kaifi J.T., et al. Insulin- like growth factor- 1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int. J. Cancer 2010, 127:1931-1940.
20. Dahlberg P.S., Jacobson B.A., Dahal G., et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann. Thorac. Surg. 2004, 78:1790-1800.
21. Agus D.B., Scher H.I., Higgins B., et al. Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999, 59:4761-4764.
22. Baselga J., Albanell J., Molina M.A., et al. Mechanism of action of trastuzumab and scientific update. Sem. Oncol. 2001, 28:4-11.
23. Stoecklein N.H., Hosch S.B., Bezler M., et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13:441-453.
24. Dreilich M., Wanders A., Brattström D., et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis. Esophagus 2006, 19:224-231.
25. Brien T.P., Odze R.D., Sheehan C.E., McKenna B.J., Ross J.S. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol. 2000, 31:35-39.
26. Yen L., You X.L., Al Moustafa A.E., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19:3460-3469.
27. Yen L., Benlimame N., Nie Z.R., et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and hetero-dimers. Mol. Biol. Cell 2002, 13:4029-4044.
28. Vogl G., Bartel H., Dietze O., Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl. Immunohistochem. Mol. Morphol. 2006, 14:138-145.
29. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
30. Spiridon C.I., Ghetie M.A., Uhr J., et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 2002, 8:1720-1730.
31. Sikder H., Huso D.L., Zhang H., et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4:291-299.
32. Alani R.M., Silverthorn C.F., Orosz K. Tumor angiogenesis in mice and men. Cancer Biol. Ther. 2004, 3:498-500.
33. Bang Y.J., van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open- label, randomised controlled trial. Lancet 2010, 376:687-697.
34. DeMeester S.R., DeMeester T.R. Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann. Surg. 2000, 231:303-321.
35. Mueller J., Stein H.J., Ouyang T., et al. Frequency and clinical impact of lymph node micrometastases and tumor cell microinvolvement in adenocarcinoma of the esophagogastric junction. Cancer 2000, 89:1874-1882.
36. Siewert J.R., Stein H.J. Adenocarcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis. Esoph. 1996, 9:173-182.
37. P.M. Schneider, P. Schweighardt, O. Stöltzing, Molecular evidence that cancer of the cardia is different from Barrett's cancer and related to proximal third gastric cancer, in: 2nd International Gastric Cancer Congress, Book of Abstracts, 1997, p. 6.
38. Ott K., Weber W.A., Fink U., et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J. Surg. 2003, 27:1035-1039.